Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Lymphoma 7Lymphoma, Large B-Cell, Diffuse 5Glioblastoma 5Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Carcinoma, Non-Small-Cell Lung 4Multiple Myeloma 3Lymphoma, Follicular 3Leukemia, Myeloid, Acute 3Gliosarcoma 3Small Cell Lung Carcinoma 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lung Neoplasms 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Erythroblastic, Acute 2Leukemia 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Graft vs Host Disease 2Glioma 2Carcinoma, Renal Cell 2

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 32Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 16Biopsy 11trametinib 10fludarabine phosphate 10dabrafenib 10spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × Vorinostat × Clear all
NCT02836548 2025-07-10

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

The Netherlands Cancer Institute

Phase 1/2 Completed
33 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡